<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03720067</url>
  </required_header>
  <id_info>
    <org_study_id>83211318.1.0000.5257</org_study_id>
    <nct_id>NCT03720067</nct_id>
  </id_info>
  <brief_title>Propranolol, Carvedilol and Rosuvastatin in the Prevention of Variceal Bleeding in Cirrhotic Portal Hypertension</brief_title>
  <acronym>Betastatin</acronym>
  <official_title>Propranolol, Carvedilol and Rosuvastatin in the Prevention of Recurrent Variceal Haemorrhage in Patients With Cirrhotic Portal Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal do Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal do Rio de Janeiro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with hepatic cirrhosis and previous variceal bleeding will be randomly assigned to
      use propranolol or carvedilol. After 8 weeks, rosuvastatin or placebo will be blindly added
      to nonresponders (HVPG measurement &gt; 12mmHg) for another 8 weeks and hemodynamic response
      will be assessed again.

      Surrogate serum markers of portal hypertension will be evaluated and correlated to HVPG
      values and to its variations.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2019</start_date>
  <completion_date type="Anticipated">December 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute hemodynamic response</measure>
    <time_frame>Two hours after a load dose of carvedilol or propranolol</time_frame>
    <description>A decrease in HVPG to 12 mmHg or lower</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Full hemodynamic response to beta blockers</measure>
    <time_frame>Eight weeks of carvedilol or propranolol</time_frame>
    <description>A decrease in HVPG to 12 mmHg or lower</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Full hemodynamic response to beta blockers plus rosuvastatin or placebo</measure>
    <time_frame>Eight weeks of beta blockers plus rosuvastatin or placebo</time_frame>
    <description>A decrease in HVPG to 12 mmHg or lower</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sufficient hemodynamic response to beta blockers plus rosuvastatin or placebo</measure>
    <time_frame>Eight weeks of beta blockers plus rosuvastatin or placebo</time_frame>
    <description>A decrease in HVPG of at least 20% from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial hemodynamic response to beta blockers plus rosuvastatin or placebo</measure>
    <time_frame>Eight weeks of beta blockers plus rosuvastatin or placebo</time_frame>
    <description>A decrease in HVPG of at least 10% from baseline</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Portal Hypertension</condition>
  <condition>Variceal Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Phase 1: Propranolol (PPL)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hepatic venous pressure gradient (HVPG) will be measured before and after 120 minutes of a loading dose of Propranolol (PPL) 80 mg PO. Thereafter, patients will receive maintenance therapy with Propranolol (40 to 320 mg / day) adjusted according to blood pressure and heart rate. After 28 days of reaching the maximum tolerated dose, a new HVPG measurement will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Carvedilol (CVD)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HVPG will be measured before and after 120 minutes of a loading dose of Carvedilol (CVD) 12.5 mg PO. Thereafter, patients will receive maintenance therapy with Carvedilol (6.25 - 25 mg / day) adjusted according to blood pressure. After 28 days of reaching the maximum tolerated dose, a new HVPG measurement will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: PPL non-responders/rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with PROPRANOLOL (PPL) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of ROSUVASTATIN 20 mg /day PO. HVPG will be measured again after 56 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: PPL non-responders/placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients treated with PROPRANOLOL (PPL) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of PLACEBO 1 tablet PO. HVPG will be measured again after 56 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: CVD non-responders/rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with CARVEDILOL (CVD) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of ROSUVASTATIN 20 mg /day PO. HVPG will be measured again after 56 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: CVD non-responders/placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients treated with CARVEDILOL (CVD) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of PLACEBO 1 tablet PO. HVPG will be measured again after 56 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>40mg to 320mg / day</description>
    <arm_group_label>Phase 1: Propranolol (PPL)</arm_group_label>
    <arm_group_label>Phase 2: PPL non-responders/placebo</arm_group_label>
    <arm_group_label>Phase 2: PPL non-responders/rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>6.25mg to 25mg / day</description>
    <arm_group_label>Phase 1: Carvedilol (CVD)</arm_group_label>
    <arm_group_label>Phase 2: CVD non-responders/placebo</arm_group_label>
    <arm_group_label>Phase 2: CVD non-responders/rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>20mg / day</description>
    <arm_group_label>Phase 2: CVD non-responders/rosuvastatin</arm_group_label>
    <arm_group_label>Phase 2: PPL non-responders/rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of rosuvastatin</description>
    <arm_group_label>Phase 2: CVD non-responders/placebo</arm_group_label>
    <arm_group_label>Phase 2: PPL non-responders/placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hepatic cirrhosis of any etiology

          -  Previous variceal bleeding

          -  Endoscopic variceal eradication at least 2 weeks before

        Exclusion Criteria:

          -  Beta blocker or statin contraindications

          -  Model for End-Stage Liver Disease (MELD) score &gt; 25

          -  Child-Pugh score &gt; 13

          -  HVPG â‰¤ 12 mmHg

          -  Creatinine clearance &lt; 50 mL/min

          -  Refractory ascites

          -  Hepatic encephalopathy stages 3 or 4

          -  Alcohol use in the last 6 months

          -  Hepatitis C treatment in the last 6 months

          -  Changing or initiating a new hepatitis B treatment in the last 6 months

          -  Malignant neoplasms from any origin except basal cell carcinoma

          -  HIV infection

          -  Pregnancy

          -  Anticoagulation

          -  Recent or complete portal vein thrombosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guilherme FM Rezende, MD, PhD</last_name>
    <phone>(5521)999976292</phone>
    <email>guimottarezende@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andre Luiz M Torres, MD</last_name>
    <phone>(5521)998588246</phone>
    <email>torres.alm@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universidade Federal do Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guilherme FM Rezende, MD, PhD</last_name>
      <phone>55-21-999976292</phone>
      <email>guimottarezende@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Andre Luiz M Torres, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>May 12, 2019</last_update_submitted>
  <last_update_submitted_qc>May 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal do Rio de Janeiro</investigator_affiliation>
    <investigator_full_name>Guilherme Rezende</investigator_full_name>
    <investigator_title>Associated Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

